Clinical Trials
-
Principal Investigator:
Sarah A. O'Shea, MDThe Parkinson's Progression Markers Initiative (PPMI) seeks to uncover insights into Parkinson's disease (PD) onset and progression that could transform how we diagnose, treat, and potentially prevent PD. PPMI has already contributed to a new understanding around disease biology and experience, and its findings and design have led to more efficient clinical research. Now PPMI is looking to bring together a larger and more diverse group of individuals both with and without PD who can help contribute to a more detailed look into the way the disease develops and changes over time. The study will... -
Principal Investigator:
Sheng-Han Kuo, MDWhy? To evaluate how brain networks are affected when frequency-specific, non-invasive, brain stimulation is applied to people with ataxia or essential tremor as compared to healthy control subjects. Who? Adults over the age of 18, diagnosed with Ataxia or Essential Tremor. What? Participation involves one clinic visit for 2-3 Hours, involving EEG measurements from the scalp (noninvasive), wearable sensors on the hand, feet, and back to measure postural movement. This will be followed by non-invasive brain stimulation during resting-state and during movement tasks. Cost to me? There is no... -
Principal Investigator:
Sheng-Han Kuo, MDWhy? To evaluate how brain networks are affected when frequency-specific, non-invasive, brain stimulation is applied to people with ataxia or essential tremor as compared to healthy control subjects. Who? Healthy adults over the age of 40, who would like to participate as controls. What? Participation involves one clinic visit for 2-3 Hours, involving EEG measurements from the scalp (noninvasive), wearable sensors on the hand, feet, and back to measure postural movement. This will be followed by non-invasive brain stimulation during resting-state and during movement tasks. Cost to me? There... -
Principal Investigator:
Christiane Reitz, MD, PhDWe are recruiting families with members under the age of 65 who have dementia or are experiencing memory problems. Our initial screening can be completed in person or over the phone. The evaluation will take about 1 to 1.5 hours per person and includes a: 1. Blood sample (5 tablespoons) or saliva (1 teaspoon) collection: These blood samples will allow us to examine genes to identify causative mutations. 2. Brief Neuropsychological Assessment. 3. Medical History: A research physician will collect basic medical information on you and your family. This assessment will provide information on... -
Principal Investigator:
Sarah A. O'Shea, MDThe DIMENSION Study is evaluating the safety and effect on cognitive symptoms of an investigational oral drug in adults with early Huntington's disease. Cognitive symptoms may include difficulty paying attention or trouble thinking through steps of an activity or complex problems. Symptoms may also include difficulty planning, remembering, and staying on task, impaired judgment, and difficulty multi-tasking. There will be an open-label extension (OLE) study, which is planned to begin later in 2022. Participants who are interested can speak to the study team. To be eligible for the study, you... -
Principal Investigator:
Karen S. Marder, MD, MPHThe aim of this study is to develop better biomarkers for the diagnosis and treatment of Lewy Body disorders. In particular, there is a need to understand how the contribution of coexisting Alzheimer's disease may affect the diagnosis and clinical course of Lewy Body disorders. This study will recruit a group of individuals with Lewy Body disorders causing cognitive impairment or dementia. Participants will have up to 4-5 visits over 3.5 years. Participants will have a comprehensive neurological evaluation, cognitive and behavior tests, and will donate blood, urine, and cerebrospinal fluid... -
Principal Investigator:
Thomas H. Brannagan III, MDThis is A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis. This is a randomized, double-blind, placebo-controlled, multicenter study. If you are eligible, you will be randomized. Randomized means the study treatment you take will be chosen for you by chance. Double-blind means that neither you nor the Study Doctor will know what treatment you will receive. Inclusion criteria must be met for a subject to be eligible for inclusion in the study: Adult males and... -
Principal Investigator:
Lawrence Sterling Honig, MD, PhDThis is a phase 2 study evaluating a new drug, AL002, in persons with early Alzheimer's Disease. Participants will be randomized to receive either AL002 or placebo, intravenously every four weeks, for a total period of about two years. The purpose is to evaluate the efficacy and safety of this drug, and this study involves pen and paper testing, and MRI and PET scans. -
Principal Investigator:
Sheng-Han Kuo, MDYou may be eligible to take part in the study because you have a diagnosis of Multiple System Atrophy (MSA) with the symptoms of neurogenic Orthostatic Hypotension (nOH). MSA is a rare disorder in adults that progresses rapidly and ultimately is a fatal neurodegenerative disease. It is characterized by autonomic failure affecting blood pressure regulation, movement and balance. Autonomic failure occurs when the autonomic nervous system, which controls functions responsible for well-being and maintaining balance, does not regulate properly. The main purpose of this study is to look at... -
Principal Investigator:
Karen L. Bell, MDWe are seeking men & women, ages 55 to 80, who have preclinical Alzheimer's disease for a 216-week treatment, multi-center, double-blind, placebo-controlled, parallel-treatment arm study to determine whether the BAN2401 study drug will reduce the risk of developing Alzheimer's disease. The study participant will receive MRI, and PET scans and will receive intravenous study drug or placebo every 2 weeks.